PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28800141-0	2018	Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.	ixazomib	76-84	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	18-23	
28800141-2	2018	However, at higher than clinical concentrations, ixazomib was metabolized by multiple CYP isoforms, with the estimated relative contribution being highest for CYP3A at 42%.	ixazomib	49-57	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	159-164	
28800141-9	2018	The clinical drug-drug interaction study results were reconciled well by a physiologically based pharmacokinetic model that incorporated a minor contribution of CYP3A to overall ixazomib clearance and quantitatively considered the strength of induction of CYP3A and intestinal P-glycoprotein by rifampin.	ixazomib	178-186	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	161-166	
28800141-10	2018	On the basis of these study results, the ixazomib prescribing information recommends that patients should avoid concomitant administration of strong CYP3A inducers with ixazomib.	ixazomib	41-49	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	149-154	
28800141-10	2018	On the basis of these study results, the ixazomib prescribing information recommends that patients should avoid concomitant administration of strong CYP3A inducers with ixazomib.	ixazomib	169-177	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	149-154	
27325500-3	2016	When investigating the proteasome inhibitors bortezomib, carfilzomib, and ixazomib, we observed increased luminescence for bortezomib and ixazomib, but not for carfilzomib, in a pregnane-X-receptor (PXR) reporter gene assay, which was inconsistent with the mRNA expression levels of the main PXR target gene CYP3A4.	ixazomib	74-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	308-314	
27325500-3	2016	When investigating the proteasome inhibitors bortezomib, carfilzomib, and ixazomib, we observed increased luminescence for bortezomib and ixazomib, but not for carfilzomib, in a pregnane-X-receptor (PXR) reporter gene assay, which was inconsistent with the mRNA expression levels of the main PXR target gene CYP3A4.	ixazomib	138-146	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	308-314